A pharmacogenetic versus a clinical algorithm for warfarin dosing.

By S. Kimmel, B. French, S. Kasner, Julie A. Johnson, Jeffrey L. Anderson, B. Gage, Y. Rosenberg, C. Eby, R. Madigan, Robert McBane and 21 more. 2013

727 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Pharmacology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jeroen J. Bax
2. P. Lancellotti
3. G. Agnelli
4. Cynthia Rudin

In Pharmacology

1. Jeroen J. Bax

Citations in the corpus

• Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing (2014, neutral): “Randomized trials have been done to evaluate clinical effectiveness , but have not yet validated the utility of genetic information [27].”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, result): “loading regimen based on the clinical data alone; no significant improvement was found in either group in terms of the TTR achieved between days 4 and 28 of therapy.(291) Lack of improvement was also shown by a trial involving 548 patients, comparing acenocoumarol or phenprocoumon loading—based on p”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “on genotype data in combination with clinical variables—with a loading regimen based on the clinical data alone; no significant improvement was found in either group in terms of the TTR achieved between days 4 and 28 of therapy.(291) Lack of improvement was”
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin dosing: 2017 Update (2017, methodology): “Dosing algorithms using genetic information outperform nongenetic clinical algorithms and fixed-dose approaches in dose prediction, except in African Americans when the algorithm only includes CYP2C9*2 and *3.(16,17,32) Genetics-based algorithms also better predict warfarin dose than the FDA-approve”
• Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, background): “However, 2 other studies did not show a difference.(198,199) As the advantage of genetic-based dosing of warfarin has not been uniformly shown, to date, adjusted-dose warfarin is the most common agent used for thromboembolism prophylaxis after hip and knee replacement surgery in the United States.”